Metalloproteinases and Recurrent Corneal Erosion Syndrome

Recurrent Corneal Erosion Syndrome Clinical Trial

— MERCURE  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02891694
• Other study ID #: EGN_2016_8
• Status: Completed
• Start date: December 2, 2016
• Est. completion date: November 26, 2020

Study information

• Verified date: December 2020
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane. The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: November 26, 2020
• Est. primary completion date: June 26, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years old
• Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
• Photorefractive surgical keratectomy (control patients)

Exclusion Criteria:

• Opposition to participation in the study
• Known pregnancy or breast-feeding patient
• No medical insurance coverage

Related Conditions & MeSH terms

• Recurrent Corneal Erosion Syndrome
• Syndrome

Intervention

Other:
• in vitro immuno-histo-chemical analysis of corneal epithelium

Locations

Country	Name	City	State
France	Fondation Opthalmologique A de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells		baseline